RxDoctor Payments Data

Marian Acevedo Alvarez, MD

Urogynecology and Reconstructive Pelvic Surgery · Maywood, ILNPI 1710271341

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,175 of the $9,922 with a category attached, or 72.3%. Coopersurgical, Inc. accounts for 72.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $4,057, 4.0 times the $1,013 reported in 2019.

$9,922in general payments, 2019–2025

Across 49 payments — averaging $202.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopersurgical, Inc.$7K
  • Boston Scientific$2K
  • Axonics, Inc.$348
  • Cook Medical LLC$295
  • Sumitomo Pharma America, Inc.$111
  • Hologic Sales And Service, LLC$94
  • plus $228 from 5 others
$24,535in research payments, 2019–2025

Across 20 payments — averaging $1226.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Urovant Sciences Inc$13K
  • Sumitomo Pharma America, Inc.$12K

What the payments were for

  • Consulting fees$7,17572%
  • Travel & lodging$4174%
  • Food & beverage$2,33023%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,922 in reported general payments places this provider in the 75th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.

See all urogynecology and reconstructive pelvic surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$57,656
Medicare patients
226
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron38$34,024
GemtesaVibegron19$17,111
Estradiol71$3,404
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$111$17,11119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.

Other urogynecology and reconstructive pelvic surgery in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →